hims & hers fda warning letter compounded semaglutide 2025 Drug compounders sue over declaration ending Wegovy shortage Hims & Hers Health, Inc.

Semaglutide: Albumin-Binding Powerhouse Semaglutide is a second-generation GLP-1 receptor agonist originally developed for type 2 diabetes and now widely used for weight loss

By creating a single molecule that can activate all three pathways, Retatrutide represents a significant, sometimes dramatic shift in research strategy

USD 2,516.2 million absolute opportunity is expected by 2036

The comparisons below draw from separate clinical trials with different designs, durations, and participant populations

Without insurance, expect to pay out of pocket for office visits ($200$400 for an initial consultation), follow-ups ($100$200 each), and any required lab work

The molecules structure, not its mechanism of action, primarily determines allergenicity